Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder.

Next Previous
Trial Profile

Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use

Most Recent Events

  • 04 Sep 2017 Primary endpoint has been met. (Differences between the study drug and placebo in the change from baseline to week 6 on the Montgomery-sberg Depression Rating Scale (MADRS)) as per results published in the European Neuropsychopharmacology
  • 04 Sep 2017 Results published in the European Neuropsychopharmacology
  • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top